Treatment for Anemia, Sickle Cell

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Barnes-Jewish Hospital, Saint Louis, MO
Anemia, Sickle Cell+2 More
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

In this prospective, single-arm, open-label, imaging and treatment study, the investigator will test the hypothesis that crizanlizumab will prevent the progression of silent cerebral infarcts in patients with sickle cell disease. Study participants will undergo brain MRI before initiation of crizanlizumab and at 6 and 30 months after starting crizanlizumab infusions. The crizanlizumab cohort will be compared to a matched, observational cohort of patients not receiving crizanlizumab.

Eligible Conditions

  • Anemia, Sickle Cell
  • Sickle Cell Disease (SCD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Anemia, Sickle Cell

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 30 months

30 months
Infarct Progression
New or enlarged silent cerebral infarcts

Trial Safety

Safety Progress

1 of 3

Other trials for Anemia, Sickle Cell

Trial Design

0 Treatment Group

31 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 30 months
Closest Location: Barnes-Jewish Hospital · Saint Louis, MO
Photo of Saint Louis  1Photo of Saint Louis  2Photo of Saint Louis  3
2006First Recorded Clinical Trial
3 TrialsResearching Anemia, Sickle Cell
156 CompletedClinical Trials

Eligibility Criteria

Age Any Age · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a history of stroke and intolerance to other therapies.
You have sickle cell disease and have had two or more sickle cell-related pain crises within the past 12 months.
You must be at least 16 years old to participate in this study.
You have intracranial or extracranial cervical artery vasculopathy.
Increased risk deemed by other objective laboratory and/or imaging results which have been associated with increased risk of cerebral infarction.
You have provided written informed consent.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.